Who are amoxicillin and metronidazole's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amoxicillin-and-metronidazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

amoxicillin and metronidazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

amoxicillin and metronidazole (amoxicillin and metronidazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antibiotic (beta-lactam + nitroimidazole). Area: Infectious Disease.

marketed Combination antibiotic (beta-lactam + nitroimidazole) Bacterial cell wall (penicillin-binding proteins) and anaerobic bacterial DNA Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

amoxicillin and metronidazole (amoxicillin and metronidazole) — University of Campinas, Brazil. This combination uses amoxicillin to inhibit bacterial cell wall synthesis and metronidazole to disrupt anaerobic bacterial DNA, providing broad-spectrum coverage against aerobic and anaerobic pathogens.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
amoxicillin and metronidazole TARGET	amoxicillin and metronidazole	University of Campinas, Brazil	marketed	Combination antibiotic (beta-lactam + nitroimidazole)	Bacterial cell wall (penicillin-binding proteins) and anaerobic bacterial DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antibiotic (beta-lactam + nitroimidazole) class)

University of Campinas, Brazil · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). amoxicillin and metronidazole — Competitive Intelligence Brief. https://druglandscape.com/ci/amoxicillin-and-metronidazole. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab